Edgewise Therapeutics, Inc. (EWTX): Price and Financial Metrics

Edgewise Therapeutics, Inc. (EWTX): $15.02

0.43 (-2.78%)

POWR Rating

Component Grades








Add EWTX to Watchlist
Sign Up

Industry: Biotech




#303 of 362

in industry

EWTX Price/Volume Stats

Current price $15.02 52-week high $20.69
Prev. close $15.45 52-week low $5.12
Day low $14.90 Volume 255,672
Day high $15.76 Avg. volume 935,819
50-day MA $17.11 Dividend yield N/A
200-day MA $10.37 Market Cap 1.40B

EWTX Stock Price Chart Interactive Chart >

Edgewise Therapeutics, Inc. (EWTX) Company Bio

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

EWTX Latest News Stream

Event/Time News Detail
Loading, please wait...

EWTX Latest Social Stream

Loading social stream, please wait...

View Full EWTX Social Stream

Latest EWTX News From Around the Web

Below are the latest news stories about EDGEWISE THERAPEUTICS INC that investors may wish to consider to help them evaluate EWTX as an investment opportunity.

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | December 25, 2023

Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

BOULDER, Colo., December 19, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET).

Yahoo | December 19, 2023

Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community

BOULDER, Colo., December 18, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the launch of an educational website dedicated to the Becker muscular dystrophy (Becker) community: www.beckermusculardystrophy.com. This is the first website solely focused on providing Becker-specific resources to help individuals and caregivers better understand the disease, learn different approaches to care and stay up to date on advocacy partne

Yahoo | December 18, 2023

Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

BOULDER, Colo., November 30, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker) and Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne. EDG-5506 is an investigational orally administered small molecule designed to

Yahoo | November 30, 2023

Speculator’s Watch List: 7 Stocks Ripe for a Short-Squeeze Windfall

Although betting against the bears is risky, the rewards for targeting short-squeeze stocks can also be stratospheric.

Josh Enomoto on InvestorPlace | November 28, 2023

Read More 'EWTX' Stories Here

EWTX Price Returns

1-mo -10.44%
3-mo 15.18%
6-mo 119.91%
1-year 115.80%
3-year -43.77%
5-year N/A
YTD 37.29%
2023 22.37%
2022 -41.49%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!